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Summary The aim of the study was to establish a model of tumour microcirculation in vivo using the murine renal cell carcinoma cell line
(RENCA) implanted into the mouse cremaster muscle, and subsequently to investigate the trafficking of syngeneic lymphocyte
subpopulations into both the RENCA tumour and the surrounding normal cremaster muscle microcirculation. We have demonstrated that
RENCA tumour cells, at a dose of 1.5 x 105 per 30,u injected into the cremaster muscle, reproducibly produced a vascularized tumour
suitable for in vivo microscopy at 10-14 days. Injection of fluorescently labelled effector cells (1 x 106) including naive splenocytes, T-cell
enriched populations and ex vivo interleukin 2 (IL-2)-activated splenocytes all migrated to and flowed through both the tumour and the normal
microcirculation, with negligible adhesion. However, we observed the selective recruitment, localization and arrest of IL-2-activated
splenocytes (P < 0.05) into the tumour microcirculation, and the subsequent extravasation of cells into the tumour intestitium in some
instances. This did not occur with the other effector cells. We also observed the absence of leucocyte rolling in the tumour microcirculation,
suggesting an impairment in adhesion molecule expression on the tumour endothelium. We have therefore established the potential of this
model for defining further effector cell-tumour-endothelium interactions.
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Adoptive immunotherapy using cytokines alone or in combination
with activated lymphocytes, such as lymphokine-activated killer
(LAK) cells, has been demonstrated to produce tumour necrosis
and a dramatic reduction in the number of metastases in a variety
of animal models (Ettinghausen and Rosenberg, 1986; Lafreniere
et al, 1988; Schwarz et al, 1988). The clinical use of adoptive
immunotherapy has been successful in the treatment of some
advanced cancers, in particular malignant melanoma and renal cell
carcinoma. Regimens using interleukin 2 (IL-2) in combination
with LAK cells demonstrated an overall response rate of 33% in
patients with renal cell carcinoma and 23% in patients with
melanoma (Rosenberg et al, 1987; Hayatt et al, 1991). However, a
much larger study involving 327 patients with advanced renal cell
carcinoma failed to show an increase in overall response rate
when comparing LAK + IL-2 (18%) with IL-2 alone (15%; Palmer
et al, 1992). Adoptive immunotherapy using tumour-infiltrating
lymphocytes (TILs) in combination with IL-2 demonstrated a40%
overall response rate in patients with renal cell carcinoma
(Rosenberg et al, 1988).
Systemic administration ofrhIL-2 alone (Rosenberg et al, 1987)
in combination with LAK cells promotes the in vivo proliferation
of LAK cells in the lungs of mice and causes tumour regression
(Ettinghausen et al, 1985). The limited numbers of patients
responding to this therapy and the potentially serious side-effects
of high-dose cytokine therapy (such as vascular leak syndrome)
highlight the need to perform preclinical studies in vitro and in
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vivo to increase our understanding ofthe mechanisms involved in
activated lymphocyte-induced anti-cancer responses. Lymphocyte
migration via the microcirculation to the site of the tumour is a
prerequisite for a therapeutic response, thus, assessment of the
ability oflymphocyte subsets to migrate to and localize within the
tumour may allow improved efficacy ofthis therapeutic approach.
Until recently, it has been difficult to assess accurately the
migration and behaviour ofadoptively transferred effector cells in
vivo. The technique of in vivo microscopy permits dynamic visu-
alization offluorescently labelled effector cells (Brown and Reed,
1997; Sasaki et al, 1991). Cells can be visualized moving through
the microcirculation, migrating across the endothelium and base-
ment membrane and localizing within the tumour. This technique
is therefore an effective method of monitoring leucocyte
trafficking in vivo. Only one study has quantified the in vivo
migration and distribution of fluorescently labelled human
adherent-LAK (A-LAK) cells into the VX2 carcinoma in the
rabbit ear chamber model using in vivo microscopy (Sasaki et al,
1991). A small numberofA-LAK cells preferentially accumulated
in the tumourmicrocirculation, butno extravasation was observed.
Adhesion ofA-LAK cells within the tumour vasculature appeared
to damage endothelial cells, and cessation of tumour blood flow
occurred 48 h after administration, followed by tumour necrosis
and a diffuse infiltration of lymphocytes, monocytes and granulo-
cytes into the tumour interstitial space. The occurrence of tumour
necrosis, despite a low effector to target cell ratio, suggested that a
decreased tumour blood flow starved the tumour of nutrients and
oxygen and that the direct cytotoxicity played a minimal role.
However, this is a xenogenic model, using human lymphocytes
and a rabbit tumour system, and interpretation of the significance
ofthese observations may have limitations.
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The present study aimed to (a) establish a model of tumour
microcirculation in vivo using the murine renal cell carcinoma cell
line (RENCA) implanted into the mouse cremaster muscle and (b)
investigate the trafficking of syngeneic lymphocyte subpopula-
tions in both the tumour and host microcirculation using fluores-
cent in vivo microscopy (IVM). The model used in these studies is
in vivo microscopy of the mouse cremaster preparation (Brown
and Reed, 1997), modified from the original technique described
in the rat (Baez, 1973). Wehave observed the selective recruitment
and localization of IL-2-activated splenocytes into the tumour
microcirculation, and established the potential of this model for
defining further effector cell, tumour endothelial interactions.
MATERIALS AND METHODS
Animals
Experiments were initially performed on 6-week-old Balb/c mice
weighing 15 g, obtained from Sheffield Field Laboratories, UK.
All experiments were approved by the Home Office and
performed within project licence number PPL 50/0695.
RENCA tumour cells
The RENCA tumour (renal cortical adenocarcinoma) arose spon-
taneously in Balb/c mice and was isolated by Dr S Stewart at the
National Cancer Institute Bethesda, ML, USA with growth and
progression after transfer ofas few as 50 viable cells (Murphy and
Hruskesky, 1980). The immunogenicity of RENCA has been
determined as being low to moderate. The RENCA tumour
becomes highly vascularized as it develops and its progressive
growth and spontaneous metastasis from the kidney occurs in a
similar manner to that generally described for human renal cell
cancer (Bassil et al, 1985).
The RENCA cell line was maintained by in vitro passage in
RPMI-1640 medium containing 1% fetal calf serum (FCS), 1%
sodium pyruvate, 10% NEAA and maintained at 37°C in a humid-
ified atmosphere of 5% carbon dioxide in air. The cell line was
routinely checked to ensure freedom from mycoplasma
(Mycoplasma rapid detection system, Gena-Probe, USA).
Preparation of spleen cells (splenocytes)
The spleens from Balb/c mice were removed aseptically and trans-
ferred to a sterile, plastic Petri dish. Using a 5-ml syringe and 23-
G needle, the spleens were ruptured and the cells dislodged gently
by flushing them out of the spleen with 10ml of RPMI-1640
medium. This process was repeated until only the connective
tissue remnants remained. Red blood cells (RBCs) were lysed by
the addition of 5 ml of RBC lysis buffer (ammonium chloride,
8.3 mg ml-'; potassium bicarbonate, 1 mg ml-'; and EDTA,
37 gg ml-' in distilled water) to the splenocyte pellet. The cells
were then washed twice in RPMI-1640 medium containing FCS,
counted and resuspended ready for use.
Fractionation of splenocytes
Nylon wool columns were prepared by packaging 0.6 g of
dried nylon wool (Division off Travenol Laboratories, Thetford,
Norfolk, UK) into 10-ml syringe barrels. The column was
saturated with RPMI-1640 medium containing 10% FCS and
Table 1 Flow cytometric analysis of leucocyte subpopulations and
integrin expression after in vitro culture with orwithout the addition of rhlL-2
(mean ± s.e.m.)
Splenocytes Antibody IL-2 activated Non-IL-2
(n=4) activated (n= 4)
T cells MAS108cs (Thy 1) 31.6 6.4% 21 .8±4.6%
CD4 cells FMAS 1 1Op (L3/L4) 17 ± 1.4% 21.8 ± 2.7%
CD8 cells FMASl 1 1c (Lyt-2) 12.9 ± 4% 11.7 ± 2.7%
Macrophages VTF-034-10 0.5% 0.4%
Integrin CD11a
Expression 276.6 ± 21% 95 ± 8.3%
Splenocytes (2 x 106 cells ml-') from normal animals (8-10 weeks) were
cultured in the presence or absence of rhIL-2 at a concentration of
1000 U ml-' in 24-well plates for 4 days. Cells were then harvested, washed
and phenotyped with a panel of antibodies (see Materials and methods).
incubated at 370C in 5% carbon dioxide in air for 45 min. An
aliquot of 1-2 x 107 splenocytes in 2 ml of medium was loaded
onto each column and incubated again for 45 min. Non-adherent
(enriched T lymphocytes) cells were eluted slowly from the
column in 20-30 ml of prewarmed medium, washed twice and
resuspended to the required concentration. Unfractionated and
nylon wool column eluted splenocytes contained 28.5 ± 6.8% and
48.1 ± 6.5% Thy 1-positive T lymphocytes respectively, measured
using flow cytometric analysis.
Preparation of in vitro activated (LAK) cells
Splenocytes were resuspended in RPMI-1640 medium supple-
mented with 10% FCS, 2 mm glutamine and 5 x 10-5 2-mer-
captoethanol at a concentration of 2 x 10 cells ml-l. Cells were
placed in a 24-well flat-bottomed tissue culture plate, 1 ml per
well, recombinant interleukin 2 (rhIL-2; 1000 U ml-'; Glaxo, UK)
was added to each well and the plates cultured for 4 days at 37°C
and 5% carbon dioxide and 95% air to induce effector cells medi-
ating LAK activity. The cells were then removed from the wells,
washed twice and resuspended in complete medium to be fluores-
cently labelled for the in vivo microscopy experiments or to use in
the cytotoxicity assays.
LAKcells are large granularlymphocytes, 95-100% expressing
a natural killer (NK) cell phenotype. The percentage of CD4
and CD8 positive T cells and macrophages was shown to be
similarforsplenocytes cultured in the presence orabsence ofrhIL-
2. However, a 31% decrease in the number ofThy 1-positive cells
was observed when cultured in the absence ofIL-2 (Table 1).
Flow cytometric assay
The following antibodies were purchased from Sera-Lab (Crawly
Down, Sussex, UK) and used at the manufacturers' recommended
concentrations for the identification of leucocyte subpopulations
and integrin expression. MAS 108cs (Thy-l), FMAS IlIc (Lyt-2),
FMAS 250 (anti-bromodeoxyuridin, used as a negative control),
VTF-034-10 (macrophages), FMAS 1lOp (L3/L4, helper/inducer),
FMAS 112p (anti-rat IgG2b) and CD lla (rat anti-mouse, Serotech,
Oxford, UK). Samples were analysed on a Becton Dickinson
FACSort (Oxford, UK) and generally 10 000 cells were acquired
with appropriate forward (FSC) and side (SSC) scatter to confirm
lymphocyte identity. The percentage and relative intensity ofFITC
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Ab binding was recorded on the whole (ungated) and lymphocyte
gated populations using 930/30 nm bandpass filterforfluorescence.
Tumour implantation
Animals were anaesthetized with an intraperitoneal injection
ofdiazepam (0.5 mg ml-', Dumex Risborough, UK) and Hypnorm
(fentanyl citrate 0.0315 mg ml-' and fluanisone 1 mg ml-', Janssen
Pharmaceutical Oxford, UK) in the ratio of 1:1 at a volume of
0.1 ml per 200 g body weight, with supplementation as required to
maintain adequate anaesthesia. An abdominal incision was made
and the testis was pulledup into the abdominal cavity viathe testic-
ular ligament, exposing the inner surface ofthe cremaster muscle.
RENCA tumour cells (1.5 x 105 cells per 30gl) were injected into
the cremaster muscle. Mice were then allowed to recover and used
for in vivo microscopy 10-14 days later, at which time the tumour
had become vascularized.
Surgical procedure for in vivo microscopy
Tumour-bearing mice were anaesthetized using the protocol
described in the previous section. A midline incision was made in
the neck and atracheostomy was performed. The left carotid artery
was cannulated and connected to apressure transducer andphysio-
graph (Micro-Med, Louisville, KY, USA) to monitor mean arterial
blood pressure and heart rate. The cannula alsoprovided access for
the administration of fluorescently labelled cells. An oesophageal
thermistor probe was inserted and connected to a thermometer
(Fluke, Washington, USA). The animal was then placed on a
warming pad to maintain body temperature (35-37°C). Another
thermistor was placed between the animal and the warming pad to
prevent over-heating. The cremaster muscle, with intact neurovas-
cular supply was prepared for in vivo microscopy, as described in
detail in a previous publication (Brown and Reed, 1997).
In vivo microscopy
The animal was transferred to the stage of a Nikon fluorescence
microscope (Orthophot) equipped with a tungsten lamp for trans-
mitted light microscopy and a mercury arc lamp for epi-illumina-
tion fluorescent light microscopy. A filter cube interposed into the
light path of the mercury arc lamp permitted blue (430-470 nm)
light to be selected for epi-illumination. Images ofthe preparation
were monitored using a silicon-intensified tube camera (SIT,
Hamammatsu Phototonics, UK), displayed on a high resolution
monitor (Sony PVM-1443) andrecorded on video (Sony SLV-373-
UB) tape for later off-line analysis.
After transferring the preparation to the microscope, a further
thermistor was placed under the edge of the cremaster and
connected to the thermometer. All instruments were calibrated
before each experiment. The animal was allowed 30 min to equili-
brate before experimentation; temperature and blood pressure
were monitored at 5-min intervals, initially, and then every 15 min
for the remainder ofthe experiment.
Fluorescent labelling of effector cells for in vivo
microscopy
Cells (1 x 107 mI-l) were incubated for 15 min at 370C with 5 jl of
the fluorochrome bis carboxy-ethyl-carboxy-fluorescein acetoxy-
methyl ester (BCECF-AM 3 gM) in medium. Cells were washed
twice and resuspended in 1 ml of medium. BCECF-AM does not
affect cell viability as assessed by trypan blue cell proliferation
using [3H]thymidine uptake (Garbett et al, 1994).
Experimental protocol
Animals were dividedinto fourgroups (n = 5 ineachgroup). During
the equilibration period, areas of interest were selected within the
cremaster muscle and the tumour, which could be clearly visualized
using transmitted or fluorescent light, and used to estimate the
numbers of lymphocytes interacting with both the tumour and the
normal microcirculation. After the equilibration period, 0.1 ml of
labelled cells (1 x 106) were injected via the carotid cannula. The
following subpopulations were assessed: (a) splenocytes, (b) nylon
wool, non-adherent splenocytes (enriched T lymphocytes), (c) in
vitro IL-2-activated lymphocytes from the spleen, and (d) in vitro
unactivated lymphocytes (-IL-2) from the spleen as controls.
Data collection and image analysis
Areas of the normal cremaster muscle were selected to estimate
that the numbers of lymphocytes within the vessels had normal
blood flow and could be clearly visualized using transmitted and
fluorescent light. The vessels studied were arterioles in the range
10-30,m, venules in the range 30-40 gm and post-capillary
venules < 5 gm. In the tumour it is difficult to categorize the
vessels, therefore an area ofinterest was chosencontaining vessels
with diameters similar to those in the normal cremaster muscle.
Lymphocytes entering the microcirculation of the normal
cremaster muscle or the RENCA tumour were subdivided into
three categories:
a. no contact with the vessel wall - flying;
b. adherent to but moving along the vessel wall - rolling;
c. adherent and stationary within the vessel for more than 30 s -
adherent.
Measurements were taken for 1 min every 10 min forthe 2-h dura-
tion ofthe study. Vessel diameters were measured using computer-
ized image analysis calibrated to produce values in microns and
vessel flow was assessed qualitatively. Numbers of fluorescently
labelled effector cells within each area of interest were counted
during each minute ofrecording.
Statistical analysis
Numbers of cells per 250 jm vessel length per minute were
expressed as median and range. The Wilcoxon signed rank test for
non-parametric data was used to analyse paired data (within group
comparison) and an ANOVA test was performed for between
group comparisons. Results were considered statistically signifi-
cant atP<0.05.
RESULTS
Characteristics of the normal and tumour
microcirculation
Tumour cells at a dose of 1.5 x 105 cells per 30 ,ul injected into the
cremaster muscle reproducibly produced a vascularized tumour of
a size 0.2-0.4 mm3 suitable for IVM after 10-14 days (data not
shown). The normal cremaster muscle microcirculation is an
organized network of vessels consisting of arterioles, capillaries,
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Table 2 Frequency of flying cells (median and range) within the RENCA
tumour and the normal cremaster microcirculation.
0 min 60 min 120 min
T N T N T N
Splenocytes 40 32 30 25 25* 15*
30-60 20-45 15-35 15-30 10-30 8-18
T lymphocytes 35 30 22 15 20* 10*
25-55 20-40 6-27 10-20 15-30 9-20
IL-2 activateda 20 8 15 10 18 12
12-40 6-20 8-20 5-14 10-20 0-20
IL-2 activatedb 24 10 18 12 15 10
control 15-28 9-20 10-22 8-18 8-24 0-12
Data, median and range; T, tumour microcirculation; N, normal
microcirculation; *P < 0.05 vs numbers of cells at time 0 min using the non-
parametric Wilcoxon test for within group comparison. aSplenocytes
incubated for 4 days at 370C in a 5% carbon dioxide atmosphere in RPMI
medium supplemented with 10% fetal calf serum, 5 x 10-5 2 ME and
1000 U ml-' rhlL-2. bSplenocytes incubated as above but in the absence of
rhlL-2.
Table 3 Frequency of adherent cells (median and range) within the RENCA
tumour and the normal cremaster microcirculation
0 min 60 min 120 min
T N T N T N
Splenocytes 1 1 1 1 1 1
0-1 0-2 0-2 0-1 0-2 0-1
Tlymphocytes 2 1 1 1 0 0
0-2 0-1 0-2 0-1 0-1 0-1
IL-2 activateda 10* 1 15* 0 12* 1
6-20 0-1 8-20 0-1 6-14 0-1
IL-2 activatedb 1 2 2 2 1 1
control 0-1 0-2 0-2 0-2 0-2 0-1
Data, median and range; T, tumour microcirculation; N, normal
microcirculation; *P < 0.05 vs control (no rhlL-2) using non-parametric
ANOVA for between group comparison. aSplenocytes incubated for 4 days at
370C in a 5% carbon dioxide atmosphere in RPMI medium supplemented
with 10% fetal calf serum, 5 x 10-5 2 ME and 1000 U ml-' rhlL-2.
bSplenocytes incubated as above but in the absence of rhlL-2.
venules and post-capillary venules. These can be identified
according to diameter and direction of blood flow. In contrast, the
RENCA tumour microcirculation is highly disorganized with an
increased number ofvessels/high power field, which are difficult to
identify because of their convoluted nature. They have numerous
bifurcations and blind ends and in the smaller tumour vessels bidi-
rectional flow as well as interrupted flow was observed.
After injection of the fluorescently labelled effector cells
(1 x 106), the number of cells entering the visual field in 1 min at
the beginning of the experiment was greater than the number
entering the same field at the end ofthe experiment for all subpop-
ulations of effector cells (Table 2). More effector cells entered the
visual field in the tumour microcirculation compared with the
normal microcirculation (Table 2). In the normal microcirculation,
the blood vessel diameters used for assessing lymphocyte interac-
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Figure 1 Comparison of flying (A) and adherent (B) rhlL-2 activated
lymphocytes in the tumour microcirculation (1) and the normal
microcirculation (E) at the beginning (0 min) and the end (120 min) of the
experiment. Data are represented as median and range above the bars with
n = 5 for each bar. *Indicates a statistically significant difference in
lymphocyte frequency between tumour and normal vessels (P < 0.05)
and < 5 ,um for the capillaries. An area in the tumour was chosen
for study, with vessels ranging up to 40 ,um. Blood flow was
assessed qualitatively, and in some areas ofthe tumour it appeared
to be greater than in the normal microcirculation.
Trafficking studies
After injection of 1 x 106 fluorescently labelled effector cells into
tumour-bearing mice, labelled cells could be visualized moving
through both the tumour and the normal microcirculation. This
allowed analysis of the number of cells adhering, rolling and
flying within the areas ofinterest.
The frequency of flying cells ranged from 12 to 60 cells in the
tumour microcirculation and from 6 to 45 in the normal microcir-
culation at the beginning of the experiment. There was a decrease
in the numbers of cells flying in both the tumour (8-30) and the
normal (0-20) microcirculation by the end of the experiment
(120 min), suggesting that the cells were being trapped somewhere
within othermicrocirculatory beds, probably in the lungs (Table 2).
No rolling cells were observed in the tumour microcirculation
with any of the effector populations used in this study. However,
only a few cells (1-3) from each of the effector populations were
capable ofrolling in the normal microcirculation at all time points
monitored.
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Naive splenocytes or T-cell-enriched populations, although able
to traffic through the tumour and normal microcirculation, did not
adhere to the endothelium. Apart from the reduction in the number
of Thy 1-positive cells, the functionally distinct, IL-2-activated
splenocytes demonstrated the same proportion ofCD4+ and CD8+
lymphocytes and macrophages as control cultured spleen cells
(Table 1). However IL-2-activated effectors demonstrated a two-
to threefold increase in fluorescent intensity in the presence ofthe
CDlla antibody when compared with controls (splenocytes), indi-
cating increased integrin expression. On injection into the tumour-
bearing mice, the number of IL-2-activated cells adhering within
the RENCA tumour microcirculation was significantly greater
(tumour vs normal; 10 vs 1; P < 0.05) when compared with the
control cultured splenocytes (Table 3). Neither population was
adherent to the normal endothelium (Table 3). Readings taken at0,
60 and 120 min were consistent, demonstrating that even after 2 h,
IL-2-activated cells were still able to adhere to the endothelium.
The localization of the cells was heterogeneous throughout all of
the tumours studied. The activated lymphocytes did not adhere
within particular areas of the tumour or in vessels of a particular
diameter, however, lymphocytes did adhere in clusters. It was
observed in two out offive experiments that some ofthe IL-2-acti-
vated cells adhering to the tumour endothelium at the beginning of
the study had extravasated into the tumour intestitium by 2 h. The
frequency of IL-2-activated splenocytes (flying and adherent)
entering either the tumour orthe normal microcirculation is shown
in Figure 1.
Physiological parameters
The heart rate, blood pressure and body temperature ofall animals
remained constant throughout the experimental period. Mean arte-
rial pressure was 100 ± 19 mmHg, and the mean pulse rate was
467 ± 50 beats per min. Body temperature, as measured by the
oesophageal thermocouple, was within the range 36.3-37.2°C.
Cremaster temperature measured with a thermocouple positioned
at the edge ofthe muscle was within the physiological range.
DISCUSSION
Previous studies have investigated the mechanisms of lympho-
cyte-mediated anti-tumour responses in vitro, but until recently it
has been difficult to accurately assess the migration and behaviour
ofadoptively transferred effector cells in vivo (Sasaki et al, 1991).
Initial studies of leucocyte and tumour cell migration used radio-
labelled effector cells and removal of the organ as assessment of
radioactivity at a specified time aftercell administration. However,
although these studies demonstrated increased migration of cells
into the liver and spleen it was thought to be due to non-specific
uptake ofreleased radiolabel into the organ (Wiltrout et al, 1983;
Basse et al, 1990). These studies allowed quantification of cell
migration but provided no information on cell behaviour and
dynamics in vivo. Fluorescent dyes have now become available
that are non-toxic to cells and allow the direct visualization of
injected effector cells, providing more accurate estimation of the
cell distribution into tissues.
Basse and his colleagues (1992) compared in vivo cell migra-
tion of radiolabelled and fluorescently labelled A-LAK cells, by
either counting radioactivity or the number of fluorescent cells in
frozen tissue sections and concluded that the latter provided a
more accurate index of A-LAK migration. Again, this study
provided valuable information on cell distribution and migration
but no information on cell dynamics.
Thetechnique ofin vivo microscopy permits thedynamic visual-
ization of fluorescently labelled effector cells and is an effective
method of monitoring lymphocyte trafflcking in vivo. A study by
Sasaki et al (1991) quantified the in vivo distribution of A-LAK
cells and observed tumour necrosis, despite a low effector to target
cell ratio. However, this was a xenogenic model using human LAK
cells in arabbit tumourimplantedintotherabbitear,thus, thesignif-
icance ofthese observations may be limited. A subsequent paperby
the same authors used a syngeneic model to investigate the migra-
tion and localization of murine activated natural killer (NK) cells
into a murine mammary carcinoma grown in a cranial window
preparation (Melder et al, 1995). They demonstrated heterogeneous
accumulation oflarge numbers ofadherent NK(A-NK) cells within
the tumourmicrocirculation butonly afew cellsadhering within the
normal pial vessels, and suggested adhesion-mediated retention of
the cells within the tumour, but mechanical entrapment ofthe rigid
activated cells within the normal microcirculation.
The results from the present study demonstrated that all the
subpopulations of effector cells migrated to the tumour but only
effector cells activated in vitro with IL-2 interacted with and
adhered to the RENCA tumourendothelium. There was adramatic
and immediate increase in the localization of IL-2-activated
splenocytes within 30 s of systemic injection of the cells. The
adherent lymphocytes remained localized within the tumour for
the duration of the study, with further cells adhering as the study
progressed. However, the localization of the cells was heteroge-
neous throughout all of the tumours studied. The activated
lymphocytes did not adhere within particular areas of the tumour
or in vessels of a particular diameter, however lymphocytes did
adhere in clusters. Some lymphocytes appeared to extravasate
through the endothelium into the tumour intestitium. These obser-
vations are in agreement withotherstudies showingheterogeneous
but specific localization of activated lymphocytes in tumour
vasculature using both xenogenic (Sasaki et al, 1991) and
syngeneic models (Basse et al, 1991; Fukumura et al, 1995;
Melder et al, 1995).
The mechanismby which LAK cells areinitially attracted to the
tumour site is not fully understood. They may gain access to the
tumour via the microcirculation simply as circulating cells, and
adhere because oftheir activated status, orpossibly respond to the
additional influence of chemoattractant agents released from
within the tumour environment, such as chemokines and
cytokines. Although LAKcells mediate an increased level ofcyto-
toxicity, this is not tumour specific (Bergers et al, 1994). Once
LAK cells have entered the tumour environment, it is unclear
whether they mediate anti-tumour activity through direct lympho-
cytotoxicity, indirectly by the release ofcytokines and the recruit-
ment ofadditional effectorcells orby interaction with andpossible
destruction ofthe tumour microcirculation.
A number of factors may enhance the localization of activated
lymphocytes within the RENCA tumour environment. These
include the architecture of the tumour vasculature (Jain, 1988), the
structure andrigidity ofin vitro activated lymphocytes (Sasaki etal,
1989) andtheexpressionofadhesionmolecules, forexampleCD11,
CD18 andCD2, on the lymphocyte surface (Melder etal, 1990).
Areas within the RENCA tumourpossessing bidirectional as well
as interrupted flow may have an increased resistance to flow, which
may increase the opportunity for lymphocytes to interact with the
tumour endothelium. Also, the increase in rigidity of the activated
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cells will obstruct their passage through smaller capillaries, thus
increasing the chance of cells lodging within the vessel. In other
areas of the tumour, the larger vessels appear to have an increased
blood flow (qualitative observation). Thus, the architecture and
possible increase inblood flow may explain the increased numberof
effector cells entering the tumour microcirculation compared with
the host microcirculation.
Lymphocytes activated by IL-2 have an increased expression of
adhesion molecules on theircell surface, including integrin subunits
and LFA-2 (Melder et al, 1990), and this was confirmed in the
present study using flow cytometry. It is unknown whether lympho-
cytes can recognize specific sites of attachment on the tumour
endothelium or whether their attachment is simply physical. At the
present time, a specific site of attachment identified for activated
cells on tumour endothelium has not been demonstrated. There is a
heterogeneous pattern of activated lymphocyte adhesion within the
tumour microcirculation, but no adhesion within the normal vessels.
However, one observation from our studies is that effector cells
within the tumour microcirculation do not roll along the endo-
thelium, a phenomenon well characterized in normal vasculature
including the cremaster muscle and during inflammation. This may
be due to the disorganized flow characteristics of the tumour
enabling firm adhesion without initial rolling. The adhesion mole-
cules P-selectin, E-selectin, L-selectin (CD62P and L) and VCAM-
1 are all involved in regulating in vivo leucocyte rolling and
adhesion (Ley et al, 1995). As rolling of effector cells was not
observed in ourstudies, itispossible thatthere is down-regulation of
adhesion molecules on the tumourendothelium, and this is currently
being investigated in our model. Previous studies using a mammary
adenocarcinoma implanted into the dorsal skinfold chamber in the
rat demonstrated reduced leucocyte adherence and rolling in the
tumourmicrocirculation comparedwiththe normalmicrocirculation
(Wu et al, 1992). This was suggested to be related to a down-regula-
tion in expression ofthe adhesion molecules ICAM-1 and ICAM-2
and the selectins on the tumour endothelium (Wu et al, 1992),
although these studies did not directly confirm this.
Thus, the architecture and blood flow within the tumour, the
rigidity of the lymphocytes and the increase in adhesion molecule
expression on the lymphocyte cell surface probably contribute to
and may determine the trafficking localization of lymphocytes
through the tumour microcirculation in our in vivo model.
In conclusion, IL-2-activated murine lymphocytes (lymphokine-
activated killer LAK cells) demonstrate a degree of selectivity for
adhesion to the murine RENCA tumour microcirculation and
possess an increased ability to distribute and localize within the
tumour microcirculation. However, because of their shape and
rigidity, and the heterogeneous blood flow within a developing
tumour, these effector cells do not have the ability to reach all
areas of the tumour, which may in part explain why variability
in the response of solid tumours to adoptive immunotherapy
occurs.
In future studies this model could be used to determine:
a. the propensity ofdifferent specifically sensitized, non-specifi-
cally activated and quiescent leucocyte populations to migrate
to and arrest within the tumour;
b. the specific adhesion molecules involved in the lymphocytes
arresting within the tumour using specific antibodies;
c. whether RENCA cells transfected with cytokine genes can
regulate the localization and adhesion oflymphocyte
subpopulations following systemic delivery.
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